With a market cap of $117.5 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious diseases. Headquartered in Princeton, New Jersey, the company has a broad portfolio of therapies spanning oncology, hematology, cardiovascular disease, immunology, and neuroscience.
BMY is expected to release its Q2 2026 earnings on Thursday, July 30, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.61 on a diluted basis, up 10.3% from $1.46 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.